Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Max Borsche; Dirk Reichel; Anja Fellbrich; Anne S Lixenfeld; Johann Rahmöller; Eva-Juliane Vollstedt; Bandik Föh; Alexander Balck; Christine Klein; Marc Ehlers; Andreas Moser

doi:10.1186/s42466-021-00135-y

Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Max Borsche, Dirk Reichel, Anja Fellbrich, Anne S Lixenfeld, Johann Rahmöller, Eva-Juliane Vollstedt, Bandik Föh, Alexander Balck, Christine Klein, Marc Ehlers, Andreas Moser

5 Citations (Scopus)

Abstract

Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

Original language	English
Journal	Neurological Research and Practice
Volume	3
Issue number	1
Pages (from-to)	34
ISSN	2524-3489
DOIs	https://doi.org/10.1186/s42466-021-00135-y
Publication status	Published - 21.06.2021

Research Areas and Centers

Research Area: Medical Genetics
Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

DFG Research Classification Scheme

2.23-07 Clinical Neurology, Neurosurgery and Neuroradiology
2.22-13 Pneumology, Thoracic Surgery
2.21-05 Immunology
2.21-04 Virology

Coronavirus related work

Research on SARS-CoV-2 / COVID-19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s42466-021-00135-y

Cite this

Borsche, M., Reichel, D., Fellbrich, A., Lixenfeld, A. S., Rahmöller, J., Vollstedt, E.-J., Föh, B., Balck, A., Klein, C., Ehlers, M., & Moser, A. (2021). Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19. Neurological Research and Practice, 3(1), 34. https://doi.org/10.1186/s42466-021-00135-y

@article{a25aefa0cf554708b0b26e168aa92bcd,

title = "Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19",

abstract = "Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.",

author = "Max Borsche and Dirk Reichel and Anja Fellbrich and Lixenfeld, \{Anne S\} and Johann Rahm{\"o}ller and Eva-Juliane Vollstedt and Bandik F{\"o}h and Alexander Balck and Christine Klein and Marc Ehlers and Andreas Moser",

year = "2021",

month = jun,

day = "21",

doi = "10.1186/s42466-021-00135-y",

language = "English",

volume = "3",

pages = "34",

journal = "Neurological Research and Practice",

issn = "2524-3489",

publisher = "BioMed Central Ltd",

number = "1",

}

Borsche, M, Reichel, D, Fellbrich, A, Lixenfeld, AS, Rahmöller, J, Vollstedt, E-J, Föh, B, Balck, A , Klein, C , Ehlers, M & Moser, A 2021, 'Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19', Neurological Research and Practice, vol. 3, no. 1, pp. 34. https://doi.org/10.1186/s42466-021-00135-y

TY - JOUR

T1 - Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

AU - Borsche, Max

AU - Reichel, Dirk

AU - Fellbrich, Anja

AU - Lixenfeld, Anne S

AU - Rahmöller, Johann

AU - Vollstedt, Eva-Juliane

AU - Föh, Bandik

AU - Balck, Alexander

AU - Klein, Christine

AU - Ehlers, Marc

AU - Moser, Andreas

PY - 2021/6/21

Y1 - 2021/6/21

N2 - Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

AB - Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

U2 - 10.1186/s42466-021-00135-y

DO - 10.1186/s42466-021-00135-y

M3 - Journal articles

C2 - 34148546

SN - 2524-3489

VL - 3

SP - 34

JO - Neurological Research and Practice

JF - Neurological Research and Practice

IS - 1

ER -

Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Abstract

Research Areas and Centers

DFG Research Classification Scheme

Coronavirus related work

UN SDGs

Access to Document

Fingerprint

Cite this